Premium
Assessment of the accuracy of an intermittent‐scanning continuous glucose monitoring device in patients with type 2 diabetes mellitus undergoing hemodialysis ( AIDT2H ) study
Author(s) -
Toyoda Masao,
Murata Takashi,
Saito Nobumichi,
Kimura Moritsugu,
Takahashi Hiroo,
Ishida Naoto,
Kitamura Makoto,
Hida Miho,
Hayashi Akinori,
Moriguchi Ibuki,
Kobayashi Naoyuki,
Tsuriya Daisuke,
Sakao Yukitoshi,
Matsushita Takaya,
Ito Yukie,
Suzuki Shota,
Kasama Shu,
Kasahara Masato,
Yamakawa Tadashi,
Mori Katsuhito,
Kuroda Akio,
Miura Junnosuke,
Hirota Yushi,
Abe Masanori,
Fukagawa Masafumi,
Sakane Naoki,
Hosoda Kiminori
Publication year - 2021
Publication title -
therapeutic apheresis and dialysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.415
H-Index - 53
eISSN - 1744-9987
pISSN - 1744-9979
DOI - 10.1111/1744-9987.13618
Subject(s) - medicine , continuous glucose monitoring , diabetes mellitus , hemodialysis , type 2 diabetes mellitus , blood glucose self monitoring , mean difference , significant difference , type 2 diabetes , surgery , type 1 diabetes , endocrinology , confidence interval
FreeStyle Libre has been approved for use in patients undergoing hemodialysis (HD) in Japan, unlike Europe and the United States; however, evidence regarding its accuracy in such patients is sparse. Forty‐one participants with type 2 diabetes undergoing HD were recruited. The overall mean absolute relative difference and mean absolute difference were 23.4% and 33.9 mg/dL, respectively. Sensor glucose levels and capillary glucose levels were significantly correlated ( r = 0.858, P < .01), although the sensor glucose levels were significantly lower than the capillary glucose levels. The accuracy of FreeStyle Libre in patients undergoing HD became deteriorated with the days of usage. The percentage of sensor results in Zones A and B in the consensus error grid analysis and in the Clarke error grid analysis were 99.7% and 99.0%, respectively. Its insufficient accuracy necessitates adjunct usage of FreeStyle Libre with self‐monitoring of blood glucose in patients undergoing HD.